Dynavax Technologies Corporation (NASDAQ: DVAX) 28.1% HIGHER; announced today that its GMP manufacturing facility in Dusseldorf, Germany has been approved for the commercial production of hepatitis B surface antigen, a key component of HEPLISAV, the Company's investigational adult hepatitis B vaccine.
The approval comes as a result of an upgrade expanding production capacity. With an updated European Union GMP manufacturing license in place, Dynavax can meet the initial commercial production demands for the anticipated launch of HEPLISAV.
hepatitis b surface antigenUnusual 11 Mid-Day Movers 12/09: DVAX, FBP, RNWK, VCI Higher; CM...StreetInsider.com News Articles Wed, 12/09/2009 - 11:43
|
